

A policy agenda to address industry influence on research integrity

Symposium 9

WCRI 2024

Quinn Grundy, Marc-André Gagnon, Scott Graham, Andreas Lundh, Lisa Parker

Disclosures

The work discussed in this Symposium was **funded** by:

- The Greenwall Foundation Making a Difference Grant (to QG)

The panel members declare **no conflicts of interest**.

Industry influence on research



Understanding industry influence on research

UCSF ALL INDUSTRIES TOBACCO OPIOIDS CHEMICAL DRUG FOOD FOSSIL FUEL Take a tour

TRUTH TOBACCO INDUSTRY DOCUMENTS Popular News About

An archive of 14 million documents created by tobacco companies about their advertising, manufacturing, marketing, scientific research and political activities, hosted by the UCSF Library.

COCHRANE EVIDENCE SYNTHESIS AND METHODS

REVIEW ARTICLE |  Open Access |  

What did the scientific literature learn from internal company documents in the pharmaceutical industry? A scoping review

Marc-André Gagnon  Miaoran Dong


First published: 27 April 2023 | <https://doi.org/10.1002/cesm.12011> | Citations: 1

TOXIC DOCS

Columbia University and the City University of New York



Millions of Pages of Previously Classified Documents on Industrial Poisons (and Counting)

Free of Charge. Open to All.

Type anything here  Advanced Search

Quick Start (5 minutes)

The need for systems thinking



Agenda
bias

FITNESS


Coca-Cola Funds Scientists Who Shift Blame for Obesity Away From Bad Diets

BY ANAHAD O'CONNOR AUGUST 9, 2015 5:25 PM 1259



An image from a video by the Coca-Cola Foundation. In November 2012, the foundation announced a \$3 million grant to Chicago's Garfield Park Conservatory Alliance. The grant was intended to establish a wellness program.

Bias in
results and
conclusions



Publication biases



The policy status quo



The NEW ENGLAND
JOURNAL of MEDICINE

HOME

ARTICLES & MULTIMEDIA ▾

ISSUES ▾

SPECIALTIES & TOPICS ▾

FOR AUTHORS ▾

CME ▶

ORIGINAL ARTICLE

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball, M.D., M.P.H., Martin M. Okun, M.D., Ph.D., David A. Williams, M.D., M.P.H., Alice B. Gottlieb, M.D., Ph.D., Kim A. Papp, M.D., Ph.D., Christos C. Zouboulis, M.D., Ph.D., April W. Armstrong, M.D., Francisco Kerdel, M.D., Michael H. Gold, M.D., Seth B. Forman, M.D., Neil J. Korman, M.D., Ph.D., Evangelos J. Giamarellos-Bourboulis, M.D., Ph.D., Jeffrey J. Crowley, M.D., Charles Lynde, M.D., Ziad Reguiat, M.D., Errol-Prospero Prens, M.D., Ph.D., Eihab Alwawi, B.S., Nael M. Mostafa, Ph.D., Brett Pinsky, Ph.D., Murali Sundaram, Ph.D., Yihua Gu, M.S., Dawn M. Carlson, M.D., M.P.H., and Gregor B.E. Jemec, M.D., D.M.Sc.
N Engl J Med 2016; 375:422-434 | August 4, 2016 | DOI: 10.1056/NEJMoa1504370

Supported by AbbVie.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Kimball reports receiving grant support and consulting fees from AbbVie, Amgen, Dermira, Janssen, and Novartis, personal fees from Medscape, and fellowship funding from Janssen; Dr. Williams, Mr. Alwawi, Drs. Mostafa, Pinsky, and Sundaram, Ms. Gu, and Dr. Carlson, being employees of AbbVie; Drs. Sundaram and Carlson, holding stock in AbbVie; Dr. Okun, having been an employee of AbbVie at the time of the study, receiving consulting fees, lecture fees, and fees for serving on an advisory board from AbbVie and holding a pending patent related to methods for the treatment of psoriasis with the use of antibodies that bind to the P40 subunit of interleukin-12, interleukin-23, or both (U.S. patent no., 8,557,239 B2); Dr. Gottlieb, receiving fees for serving on advisory boards from AbbVie, Amgen, Centocor (Janssen), Coronado, Eli Lilly, Novartis, Pfizer, Actelion, Astellas, Beiersdorf, Novo Nordisk, UCB Pharma, Vertex, Genentech, TEVA, XenoPort, Baxalta, and Kineta One and consulting fees from AbbVie, Amgen, Celgene, Centocor (Janssen), Coronado, Eli Lilly, Novartis, Pfizer, Actelion, Akros, Astellas, Beiersdorf, Bristol-Myers Squibb, Canfit, Catabasis, CSL Behring Biotherapies for Life, Dermipor, GlaxoSmithKline, Incyte, Karyopharm, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Development America, Novo Nordisk, Takeda, UCB Pharma, Vertex, Genentech, TEVA, XenoPort, Baxalta, and Kineta One, and grant support from AbbVie, Amgen, Baxalta, Celgene, Centocor (Janssen), Coronado, Eli Lilly, Novartis, Pfizer, Levia, Merck, XenoPort, Dermira, and Kineta One; Dr. Papp, receiving fees for serving on advisory boards from AbbVie, Amgen, Astellas, Celgene, Galderma, Janssen, Janssen-Cilag, LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Incyte, Regeneron, Takeda, and UCB Pharma, consulting fees from AbbVie, Amgen, Astellas, Celgene, Galderma, Janssen, LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Incyte, Regeneron, Takeda, UCB Pharma, Actelion, Akesis, Akros, Anacor, Bayer, Coherus, Dermira, Ferring, Genentech, GlaxoSmithKline, Kyowa, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mylan, and Sosei, lecture fees from AbbVie, Amgen, Astellas, Celgene, Galderma, Janssen, LEO Pharma, Merck Sharp & Dohme, Novartis, and Pfizer, and grant support from AbbVie, Amgen, Astellas, Celgene, Galderma, Janssen, LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Incyte, Regeneron, Takeda, UCB Pharma, Anacor, Coherus, Dermira, Genentech, GlaxoSmithKline, Kyowa, and MedImmune; Dr. Zouboulis, receiving fees for serving on scientific advisory boards from Celgene, lecture fees from AbbVie, and grant support through his institution from Celgene and Novartis; Dr. Armstrong, receiving consulting fees from AbbVie, Amgen, Celgene, Merck, Eli Lilly, Novartis, Pfizer, Janssen, and UCB Pharma, and grant support from AbbVie, Eli Lilly and Janssen; Dr. Kerdel, receiving fees for board membership from Celgene, lecture fees from Amgen, Galderma, Janssen, Pfizer, Celgene, Steifel, and LEO Pharma, honoraria from AbbVie, and grant support from AbbVie, Amgen, Galderma, Janssen, Pfizer, Celgene, Novartis, AstraZeneca, and Valeant; Dr. Gold, receiving honoraria from AbbVie, Amgen, Novartis, and Pfizer and grant support from Celgene, Amgen, Janssen and Pfizer, Promius, Merck, Maruho, Watson, Regeneron, and Pfizer; Dr. Forman, receiving consulting fees from AbbVie, Galderma, Cellceutix, and Psoria-Light, lecture fees from AbbVie and Novartis, and grant support from AstraZeneca, Janssen, Novartis, Promius, Regeneron, Incyte, Pfizer, Eli Lilly, and Valeant; Dr. Korman, receiving consulting fees and grant support from Amgen, Celgene, Dermira, Eli Lilly, Centocor (Janssen), Merck, Novartis, and Pfizer; Dr. Giamarellos-Bourboulis, receiving honoraria from AbbVie, Astellas, Biotest, Brahms, and The Medicines Company, all paid to his institution, and grant support through his institution from AbbVie, Biotest, Astellas, European FrameWork7 Program HemoSpec, Sanofi, Swedish Orphan Biovitrum, Thermo Scientific Brahms, and The Medicines Company; Dr. Crowley, receiving lecture fees and fees for serving on advisory boards from AbbVie, Amgen, Celgene, Eli Lilly, and Novartis and grant support through his institution from AbbVie, AstraZeneca, Amgen, Celgene, Janssen, Eli Lilly, Pfizer, Maruho, Merck, Novartis, Regeneron, and Sandoz; Dr. Lynde, receiving consulting and lecture fees from AbbVie, Janssen, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, and Regeneron; Dr. Reguiat, receiving fees for serving on advisory boards from AbbVie, Janssen-Cilag, Novartis, and Pfizer, lecture fees from AbbVie, Janssen-Cilag, Novartis, Pfizer, GlaxoSmithKline, and LEO Pharma, and grant support from AbbVie, Janssen-Cilag, Novartis, Pfizer, Actelion, Amgen, and GlaxoSmithKline; Dr. Prens, receiving lecture fees and fees for serving on advisory boards from AbbVie, Amgen, Celgene, Janssen-Cilag, Galderma, Pfizer, and Novartis and grant support through his institution from AbbVie, Janssen-Cilag, AstraZeneca, and Pfizer; and Dr. Jemec, receiving fees for serving on advisory boards from AbbVie, Merck Sharp & Dohme, and Pfizer, lecture fees from AbbVie, Merck Sharp & Dohme, LEO Pharma, and Galderma, and grant support from AbbVie, Actelion, Janssen-Cilag, LEO Pharma, Novartis, and Regeneron. No other potential conflict of interest relevant to this article was reported.

Moving beyond conflict of interest



Need for policy, systems, and structural action

Panelists:

Marc-André Gagnon, Associate Professor, School of Public Policy and Administration, Carleton University

Scott Graham, Associate Professor in the Department of Rhetoric & Writing at the University of Texas at Austin

Andreas Lundh, Associate Professor, Cochrane Denmark & Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark

Lisa Parker, Honorary Senior Lecturer, The University of Sydney, Australia

Followed by Q&A and panel discussion.